A novel DNA-based switch that enables the one-step quantitative detection of antibodies in complex samples (such as whole blood) and effectively reduces analysis time from a few hours to less than 5 minutes.
Despite the great importance of antibodies in biotechnology and as molecular markers for the diagnosis of many disease states, current methods for their quantitative detection in complex samples are cumbersome and protracted procedures. While the use of biomolecular switches for rapid detection of disease markers (DNA, RNA, proteins, etc.) in complex samples has been successful in simplifying clinical diagnostic procedures for many diseases, similar methods for the one-step quantitative detection of antibodies do not currently exist. Thus, more efficient methods for quantitative antibody detection could drastically speed up the clinical diagnosis process.
Researchers at the University of California, Santa Barbara have developed a novel DNA-based switch, called “antibody beacon”, that enables the one-step quantitative detection of antibodies in complex samples (such as whole blood) and effectively reduces analysis time from a few hours to less than 5 minutes. The switches support a multitude of readout mechanisms such as optical, electrochemical, and catalytical outputs via a binding-induced structural change. As such, the antibody beacons are extremely versatile, and can be engineered to recognize virtually any antibody against small molecules (e.g. DNP or Dig), peptides (HIV epitode), and proteins. Finally, the switches are exceptionally cheap to produce, making them an ideal solution for the fast and quantitative detection of antibodies.
This technology is available for licensing. Patent Pending.
|United States Of America||Issued Patent||9,828,628||11/28/2017||2011-023|
antibody detection, DNA-based switch, indpharma